BR112012007252A2 - uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer - Google Patents

uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer Download PDF

Info

Publication number
BR112012007252A2
BR112012007252A2 BR112012007252-8A BR112012007252A BR112012007252A2 BR 112012007252 A2 BR112012007252 A2 BR 112012007252A2 BR 112012007252 A BR112012007252 A BR 112012007252A BR 112012007252 A2 BR112012007252 A2 BR 112012007252A2
Authority
BR
Brazil
Prior art keywords
antibody
notch3
notch1
antagonist
nrr
Prior art date
Application number
BR112012007252-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian W. Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012007252A2 publication Critical patent/BR112012007252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112012007252-8A 2009-09-30 2010-09-29 uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer BR112012007252A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30
US61/247,298 2009-09-30
PCT/US2010/050610 WO2011041336A2 (en) 2009-09-30 2010-09-29 Methods of treating cancer using notch antagonists

Publications (1)

Publication Number Publication Date
BR112012007252A2 true BR112012007252A2 (pt) 2020-08-11

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007252-8A BR112012007252A2 (pt) 2009-09-30 2010-09-29 uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer

Country Status (21)

Country Link
US (1) US9200071B2 (https=)
EP (1) EP2483311B1 (https=)
JP (3) JP6025563B2 (https=)
KR (1) KR101782180B1 (https=)
CN (1) CN102630229B (https=)
AU (1) AU2010300747A1 (https=)
BR (1) BR112012007252A2 (https=)
CA (1) CA2775880A1 (https=)
CL (1) CL2012000800A1 (https=)
CO (1) CO6531430A2 (https=)
CR (1) CR20120213A (https=)
EC (1) ECSP12011858A (https=)
ES (1) ES2580229T3 (https=)
IL (1) IL218662A0 (https=)
MA (1) MA33973B1 (https=)
MX (1) MX342250B (https=)
PE (1) PE20120998A1 (https=)
PH (1) PH12012500574A1 (https=)
RU (1) RU2012117619A (https=)
WO (1) WO2011041336A2 (https=)
ZA (1) ZA201201984B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133796C1 (ru) * 1997-10-09 1999-07-27 ОАО "Томский электромеханический завод им.В.В.Вахрушева" Люк смотрового колодца
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JP6059985B2 (ja) 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体
SG191039A1 (en) 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
HK1214282A1 (zh) * 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
JP2016520289A (ja) * 2013-03-15 2016-07-14 オンコメッド ファーマシューティカルズ インコーポレイテッド 膵臓癌の治療方法
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
PL3105253T3 (pl) * 2014-02-12 2018-12-31 F. Hoffmann-La Roche Ag Przeciwciała anty-Jagged1 i sposoby stosowania
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
DK3448420T3 (da) * 2016-04-29 2022-12-12 Aveo Pharmaceuticals Inc Anti-notch3-antistof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
AR063494A1 (es) 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
EP2125887A4 (en) * 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN104402998A (zh) * 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP6059985B2 (ja) * 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体

Also Published As

Publication number Publication date
IL218662A0 (en) 2012-05-31
MX2012003851A (es) 2012-05-08
ECSP12011858A (es) 2012-06-29
ES2580229T3 (es) 2016-08-22
EP2483311B1 (en) 2016-05-18
US20120328608A1 (en) 2012-12-27
JP2017014219A (ja) 2017-01-19
CA2775880A1 (en) 2011-04-07
MX342250B (es) 2016-09-22
PE20120998A1 (es) 2012-08-14
KR101782180B1 (ko) 2017-10-23
KR20120100952A (ko) 2012-09-12
RU2012117619A (ru) 2013-11-10
JP2013506675A (ja) 2013-02-28
CN102630229A (zh) 2012-08-08
JP6025563B2 (ja) 2016-11-16
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
CO6531430A2 (es) 2012-09-28
HK1170505A1 (en) 2013-03-01
EP2483311A2 (en) 2012-08-08
WO2011041336A2 (en) 2011-04-07
US9200071B2 (en) 2015-12-01
CR20120213A (es) 2012-07-09
WO2011041336A3 (en) 2012-05-03
PH12012500574A1 (en) 2012-10-22
ZA201201984B (en) 2013-05-29
MA33973B1 (fr) 2013-02-01
JP2015145362A (ja) 2015-08-13
CL2012000800A1 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
BR112012007252A2 (pt) uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer
TWI874309B (zh) 用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
TWI775781B (zh) 癌症之治療性及診斷性方法
US10980894B2 (en) Antibodies, pharmaceutical compositions and methods
BR112020026819A2 (pt) anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
HK1255067A1 (zh) 抗c10orf54抗体及其用途
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
JP2018529719A (ja) Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
JP7090545B2 (ja) Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
WO2016063026A2 (en) Selective nav protein binders
CN103890007A (zh) 神经调节蛋白抗体及其用途
US20190389963A1 (en) Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
US20250163150A1 (en) Combination therapies comprising a kras inhibitor for the treatment of cancer
WO2021092196A9 (en) Anti-tigit antibodies and uses thereof
TW202126690A (zh) 用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
JPWO2011007853A1 (ja) 癌特異的アイソフォームに対するモノクローナル抗体
JP2014510044A (ja) 抗ｅｇｆｌ７抗体を用いた治療のための投与
US8691222B2 (en) NLRR-1 antagonists and uses thereof
US20150183860A1 (en) Regimens for treatments using anti-igf antibodies
HK1170505B (en) Methods of treating notch1-antagonist-resistant cancer(s) using notch3 antagonists
HK40074885A (en) Anti-c10orf54 antibodies and uses thereof
HK40016679A (en) Therapeutic and diagnostic methods for cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]